GlassScriptPhysician profile
Deja Rose
NPI 1710331459
$5,665.78
in general payments reported to CMS, 2019-2025
28 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,825 · 2022: $259 · 2023: $113 · 2024: $1,292 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,068.01 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $331.47 | 2024-2025 | |
| Abbvie INC. | $260.75 | 2024-2025 | |
| Biogen, INC. | $223.25 | 2024-2025 | Vumerity, Tysabri, Leqembi |
| Tg Therapeutics, INC. | $200.34 | 2024-2025 | |
| Genentech, INC. | $151.84 | 2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $136.85 | 2024-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $133.33 | 2022-2024 | |
| Amgen INC. | $115.84 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $112.61 | 2023 | Uplizna |
| Mallinckrodt Hospital Products INC. | $91.48 | 2024-2025 | Acthar |
| Acadia Pharmaceuticals INC | $88.32 | 2025 | Nuplazid |
| Lundbeck LLC | $88.14 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $78.24 | 2024 | Ponvory |
| Neurocrine Biosciences, INC. | $73.52 | 2024-2025 | Ingrezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $70.01 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Grifols USA, LLC | $57.73 | 2024-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $55.32 | 2024 | Ultomiris, Soliris |
| Pfizer INC. | $54.79 | 2024-2025 | |
| Lilly USA, LLC | $46.20 | 2024 | Kisunla, Emgality |
| Genentech USA, INC. | $34.56 | 2024-2025 | Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $34.33 | 2025 | Hyqvia |
| Ge Healthcare | $32.77 | 2025 | |
| Neurelis, INC. | $27.98 | 2024 | Valtoco |
| Abbott Laboratories | $27.33 | 2025 | Infinity |
| Catalyst Pharmaceuticals, INC. | $24.03 | 2024 | |
| Ucb, INC. | $23.86 | 2024 | Rystiggo |
| Jazz Pharmaceuticals INC. | $22.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deja Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.